<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cidofovir: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cidofovir: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cidofovir: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin Rodriguez, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kimon C Zachary, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 23, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> was the first nucleotide analog approved for clinical use. The drug has been employed almost exclusively to treat cytomegalovirus (CMV) infections in patients with the acquired immunodeficiency syndrome (AIDS) and transplant recipients. However, cidofovir is also used as a therapeutic option against other viral infections. (See  <a class="medical medical_review" href="/z/d/html/3746.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> is a monophosphate nucleotide analog. After undergoing cellular phosphorylation to its diphosphate form, it competitively inhibits the incorporation of deoxycytidine triphosphate (dCTP) into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation [<a href="#rid1">1</a>]. Unlike nucleoside analogs such as <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> or <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>, cidofovir is not phosphorylated (and hence activated) by a viral kinase.</p><p class="headingAnchor" id="H3"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> demonstrates in vitro activity against a number of DNA viruses, including the herpesviruses, adenovirus, polyomavirus, papillomavirus, and poxvirus [<a href="#rid2">2</a>]. Cidofovir also retains activity against thymidine kinase-negative herpes simplex virus (HSV) and UL97 phosphotransferase-negative CMV, which are mutant viruses resistant to <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">acyclovir</a> and <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>. Clinical efficacy has been demonstrated rigorously only against CMV. Its clinical utility in infections caused by other viral pathogens remains to be determined [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H4"><span class="h1">MECHANISM OF RESISTANCE</span><span class="headingEndMark"> — </span>Reduced susceptibility of CMV to <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> has been associated with mutations in the viral DNA polymerase gene [<a href="#rid3">3,4</a>]. Since its mechanism of action does not require phosphorylation, cidofovir is unaffected by mutations in CMV phosphotransferase which confer resistance to <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>. However, prolonged therapy with ganciclovir in patients with CMV infections has been associated with the emergence of viral DNA polymerase mutations which confer cross-resistance to cidofovir [<a href="#rid4">4-8</a>].</p><p class="headingAnchor" id="H5"><span class="h1">BASIC PHARMACOKINETICS</span><span class="headingEndMark"> — </span>Administration of a single dose of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> (3 to 5 mg/kg intravenous [IV]) yields peak plasma concentrations of 7.3 to 11.5 mg/L. Over 80 percent of the drug is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours [<a href="#rid1">1</a>]. However, cidofovir diphosphate, an active metabolite, is eliminated more slowly with first and second phase intracellular half-lives of 24 and 65 hours, respectively [<a href="#rid1">1</a>]. This property permits the drug to be dosed every two weeks.</p><p>The most important toxicity of the drug is renal, which can be reduced by coadministration with <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> and <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a>; probenecid blocks active renal tubular secretion (see <a class="local">'Toxicity'</a> below). Dosing probenecid prior to, two hours after, and eight hours after <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> infusion may result in the doubling of serum concentrations [<a href="#rid1">1</a>]. The fact that probenecid protects against nephrotoxicity and yet decreases renal clearance of the drug may seem paradoxical. However, the drug appears to prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells; at the same time, drug concentrations can decrease more slowly since these same renal cells are responsible for secreting the drug into the urine.</p><p class="headingAnchor" id="H6"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>As noted above, the most important toxicity of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> is dose-dependent nephrotoxicity; the drug is contraindicated in persons with proteinuria (2+ or greater) or baseline serum creatinine greater than 1.5 mg/dL. Cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting [<a href="#rid9">9,10</a>]. Alternative formulations, such as <a class="drug drug_general" data-topicid="131802" href="/z/d/drug information/131802.html" rel="external">brincidofovir</a> (CMX001), an oral prodrug of cidofovir, may have less nephrotoxicity, though studies of prophylaxis against CMV showed suboptimal results [<a href="#rid11">11,12</a>]. </p><p>To monitor for nephrotoxicity, serum creatinine and urine protein (dipstick is acceptable) should be checked within 48 hours prior to each dose of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, and dose reduction or discontinuation is required for evidence of renal dysfunction. Approximately 50 percent of patients receiving cidofovir in clinical trials developed either proteinuria (2+ or greater), increased serum creatinine (rise of at least 0.4 mg/dL), or decreased creatinine clearance (55 mL/min or less) [<a href="#rid9">9</a>].</p><p>Renal dysfunction is usually reversible with discontinuation of the drug. However, a few cases of end-stage kidney disease associated with the use of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> in HIV-positive individuals have been reported [<a href="#rid13">13,14</a>]. Topical or intralesional use of cidofovir may also be rarely associated with renal dysfunction and monitoring may be necessary [<a href="#rid15">15,16</a>]. The systemic absorption of cidofovir after topical application is probably higher if applied to nonintact skin.</p><p>Patients should receive 1 liter of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> over one to two hours immediately preceding the <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> dose and, if they can tolerate the fluid load, a second liter either during or immediately following the drug [<a href="#rid9">9</a>]. Patients must also receive <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> (2 g orally three hours prior and 1 g two and eight hours following cidofovir) [<a href="#rid9">9</a>].</p><p>Nausea and vomiting are common side effects of <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> and may be reduced by giving the drug with food or by administration of antiemetics. Rash is also common and management with an antihistamine and/or <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> may be appropriate [<a href="#rid9">9</a>].</p><p>Neutropenia has been observed in approximately 20 percent of patients receiving <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> [<a href="#rid9">9</a>], though it is difficult to establish causality for this finding given its common appearance in advanced AIDS. In rats, cidofovir has been associated with mammary adenocarcinoma and thus it should be regarded as a potential human carcinogen [<a href="#rid9">9</a>].</p><p>Acute iritis and ocular hypotony, which have precluded intravitreal administration, have also been associated with IV <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> [<a href="#rid17">17,18</a>]. However, when evaluating a patient with ocular inflammation who is receiving both cidofovir for CMV retinitis and antiretroviral therapy for HIV, one must also consider the possibility of vitritis associated with an immune reconstitution inflammatory syndrome. (See  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis", section on 'CMV immune reconstitution inflammatory syndromes'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">USE IN PREGNANCY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> is embryotoxic in rats and rabbits, and there are no adequate studies in pregnant females. Females of childbearing potential should use contraception during and for one month following treatment with cidofovir, and males who have sex with females of childbearing potential should use barrier contraception during and for three months after treatment [<a href="#rid9">9</a>].</p><p><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> should be used in pregnant females only if the potential benefits outweigh the risk to the fetus.</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL USE OF CIDOFOVIR</span><span class="headingEndMark"> — </span>IV <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> has only been rigorously studied in patients with AIDS for treatment of CMV retinitis. Although IV cidofovir is sometimes used in the treatment of other viral infections, data are limited to case reports or case series. There have also been case reports and small series describing the use of topical cidofovir for the treatment of infections such as acyclovir-resistant herpes simplex virus (HSV) [<a href="#rid19">19</a>], human papillomavirus-related warts [<a href="#rid20">20</a>], and molluscum contagiosum [<a href="#rid20">20,21</a>]. However, no US Food and Drug Administration-approved topical formulation of cidofovir is available. </p><p>Guidance on the use of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> for treatment of specific infections is presented separately. (See  <a class="medical medical_review" href="/z/d/html/3731.html" rel="external">"Treatment of AIDS-related cytomegalovirus retinitis", section on 'Relapsed infection'</a> and  <a class="medical medical_review" href="/z/d/html/3750.html" rel="external">"AIDS-related cytomegalovirus neurologic disease", section on 'Cidofovir'</a> and  <a class="medical medical_review" href="/z/d/html/8348.html" rel="external">"Diagnosis, treatment, and prevention of adenovirus infection", section on 'Cidofovir'</a> and  <a class="medical medical_review" href="/z/d/html/16701.html" rel="external">"Treatment of drug-resistant genital herpes simplex virus infection in patients with HIV", section on 'Topical therapies'</a> and  <a class="medical medical_review" href="/z/d/html/6303.html" rel="external">"Common causes of hoarseness in children", section on 'Papillomatosis'</a> and  <a class="medical medical_review" href="/z/d/html/8296.html" rel="external">"Vaccines to prevent smallpox, mpox (monkeypox), and other orthopoxviruses", section on 'Antiviral agents'</a> and  <a class="medical medical_review" href="/z/d/html/7338.html" rel="external">"Kidney transplantation in adults: BK polyomavirus-associated nephropathy", section on 'Adjunctive therapies'</a> and  <a class="medical medical_review" href="/z/d/html/16146.html" rel="external">"Human herpesvirus 6 infection in hematopoietic cell transplant recipients", section on 'Antiviral selection'</a> and  <a class="medical medical_review" href="/z/d/html/8295.html" rel="external">"Treatment and prevention of mpox (monkeypox)", section on 'Specific agents'</a>.)</p><p class="headingAnchor" id="H1177297"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action – </strong><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> is a monophosphate nucleotide analog of deoxycytidine triphosphate (dCTP). After undergoing cellular phosphorylation, cidofovir competitively inhibits the incorporation of dCTP into viral DNA by viral DNA polymerase. Incorporation of the drug disrupts further chain elongation. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity – </strong><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> demonstrates in vitro activity against a number of DNA viruses, including adenovirus, polyomavirus, papillomavirus, poxvirus, and the herpesviruses (including acyclovir-resistant strains of herpes simplex virus [HSV]). Clinical efficacy has been demonstrated rigorously only against cytomegalovirus (CMV) infection. (See <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of resistance – </strong>Reduced susceptibility of CMV to <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> has been associated with mutations in the viral DNA polymerase gene. (See <a class="local">'Mechanism of resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Basic pharmacokinetics – </strong>Over 80 percent of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> is excreted unchanged in the urine within 24 hours, with a half-life of 2.4 to 3.2 hours. However, its active metabolite is eliminated more slowly, which permits drug dosing every two weeks. (See <a class="local">'Basic pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most important toxicity of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> is dose-dependent nephrotoxicity; cidofovir has been associated with decreased renal function and the emergence of a Fanconi-type syndrome, with proteinuria, glucosuria, and bicarbonate wasting. Cidofovir is contraindicated in persons with significant proteinuria or with a baseline serum creatinine greater than 1.5 mg/dL. (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should receive 1 liter of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> over one to two hours immediately preceding <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> dosing. If they can tolerate the fluid load, a second liter should be given either during or immediately following cidofovir administration. Patients must also receive <a class="drug drug_general" data-topicid="9812" href="/z/d/drug information/9812.html" rel="external">probenecid</a> (2 g orally three hours prior and 1 g two and eight hours following cidofovir), which may prevent damage to proximal renal tubular epithelial cells by preventing the uptake of cidofovir into these cells. (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in pregnancy – </strong><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> should be used in pregnant females only if the potential benefits outweigh the risk to the fetus. (See <a class="local">'Use in pregnancy'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lea AP, Bryson HM. Cidofovir. Drugs 1996; 52:225.</a></li><li><a class="nounderline abstract_t">De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev 2003; 16:569.</a></li><li><a class="nounderline abstract_t">Cherrington JM, Fuller MD, Lamy PD, et al. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J Infect Dis 1998; 178:1821.</a></li><li><a class="nounderline abstract_t">Erice A, Gil-Roda C, Pérez JL, et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175:1087.</a></li><li><a class="nounderline abstract_t">Chou S, Marousek G, Guentzel S, et al. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176:786.</a></li><li><a class="nounderline abstract_t">Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55:459.</a></li><li><a class="nounderline abstract_t">Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23:689.</a></li><li><a class="nounderline abstract_t">Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010; 50:733.</a></li><li class="breakAll">Vistide. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/020638s003lbl.pdf (Accessed on June 19, 2023).</li><li><a class="nounderline abstract_t">Vittecoq D, Dumitrescu L, Beaufils H, Deray G. Fanconi syndrome associated with cidofovir therapy. Antimicrob Agents Chemother 1997; 41:1846.</a></li><li><a class="nounderline abstract_t">Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369:1227.</a></li><li><a class="nounderline abstract_t">Marty FM, Winston DJ, Chemaly RF, et al. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019; 25:369.</a></li><li><a class="nounderline abstract_t">Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948.</a></li><li><a class="nounderline abstract_t">Meier P, Dautheville-Guibal S, Ronco PM, Rossert J. Cidofovir-induced end-stage renal failure. Nephrol Dial Transplant 2002; 17:148.</a></li><li><a class="nounderline abstract_t">Naiman AN, Roger G, Gagnieu MC, et al. Cidofovir plasma assays after local injection in respiratory papillomatosis. Laryngoscope 2004; 114:1151.</a></li><li><a class="nounderline abstract_t">Bienvenu B, Martinez F, Devergie A, et al. Topical use of cidofovir induced acute renal failure. Transplantation 2002; 73:661.</a></li><li><a class="nounderline abstract_t">Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.</a></li><li><a class="nounderline abstract_t">Friedberg DN. Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:801.</a></li><li><a class="nounderline abstract_t">Lalezari J, Schacker T, Feinberg J, et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis 1997; 176:892.</a></li><li><a class="nounderline abstract_t">Alsaleemi A, O'Connor C, Irvine AD, Leahy TR. Topical cidofovir for the treatment of recalcitrant viral warts and molluscum contagiosum in Jacobsen syndrome. Pediatr Dermatol 2020; 37:1191.</a></li><li><a class="nounderline abstract_t">van der Wouden JC, van der Sande R, Kruithof EJ, et al. Interventions for cutaneous molluscum contagiosum. Cochrane Database Syst Rev 2017; 5:CD004767.</a></li></ol></div><div id="topicVersionRevision">Topic 8297 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8841740" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557287" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815243" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9129070" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9291334" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21078929" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20930070" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antiviral drug resistance of human cytomegalovirus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100090" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cytomegalovirus resistance testing: pitfalls and problems for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100090" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cytomegalovirus resistance testing: pitfalls and problems for the clinician.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257778" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Fanconi syndrome associated with cidofovir therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24066743" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30292744" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589927" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cidofovir-induced end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11773481" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cidofovir-induced end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15235339" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cidofovir plasma assays after local injection in respiratory papillomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11889450" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Topical use of cidofovir induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9194724" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9194736" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypotony and visual loss with intravenous cidofovir treatment of cytomegalovirus retinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9333146" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32897593" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Topical cidofovir for the treatment of recalcitrant viral warts and molluscum contagiosum in Jacobsen syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28513067" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Interventions for cutaneous molluscum contagiosum.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
